Recommendation of the President – dysopyramide
On 11 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 11/2025 on the legitimacy of issuing consent for reimbursement within the framework of the targeted import of dysopyramide active substance for the indications: supraventricular arrhythmias (atrial fibrillation, atrial flutter, atrial tachycardia, atrial premature beats), ventricular arrhythmias (ventricular premature beats, ventricular tachycardia, ventricular fibrillation and flutter), hypertrophic cardiomyopathy with left ventricular outflow tract narrowing